Form 4: Adaptimmune Therapeutics Executive Exercises and Sells Shares to Cover Tax Obligations

Cintia Piccina, Chief Commercial Officer of Adaptimmune Therapeutics, exercised RSU-style share options and sold a portion of the acquired American Depositary Shares (ADS) to cover tax withholding obligations.

Summary

• Cintia Piccina, the Chief Commercial Officer of Adaptimmune Therapeutics PLC, executed a transaction involving the company's stock on January 15, 2025.
• She exercised 25% of the remaining balance of an RSU-style share option granted on March 18, 2024, which had vested.
• This exercise resulted in the acquisition of 12,991 American Depositary Shares (ADS), each representing six ordinary shares of Adaptimmune.
• To cover tax withholding obligations and associated sale costs, Ms. Piccina sold these ADSs at a weighted average price of $0.5748, with individual transactions ranging from $0.57 to $0.595.
• The sale was executed automatically under Adaptimmune's option plan, a 'Sell to Cover' exercise.
• Following the transaction, Ms. Piccina directly holds 18,421 ADSs, in addition to 92,652 ADSs and options covering 6,779,928 ordinary shares.

Sentiment

Score: 6

Explanation: The document reflects a neutral sentiment as it reports a standard transaction related to executive compensation. There are no indications of positive or negative performance, strategic shifts, or significant risks.

Positives

• The 'Sell to Cover' mechanism simplifies option exercises for employees by automatically handling tax obligations.

Industry Context

This transaction is a routine part of executive compensation and stock ownership, common in publicly traded companies. The 'Sell to Cover' mechanism is a standard practice to facilitate option exercises while managing tax liabilities.

Comparison to Industry Standards

• Executive stock option exercises and subsequent sales to cover taxes are common practice across publicly traded companies, including those in the biotechnology sector like Gilead Sciences, Amgen, and Biogen.
• The 'Sell to Cover' method is a standard mechanism used by companies to simplify the process for employees and ensure compliance with tax regulations, similar to practices at companies like Regeneron and Vertex Pharmaceuticals.
• The size of the transaction and the number of shares involved are typical for executive-level stock option exercises in companies of Adaptimmune's size and market capitalization.

Stakeholder Impact

• The transaction has a minimal direct impact on shareholders, employees, customers, suppliers, or creditors, as it is a routine executive compensation matter.

Key Dates